Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29540729)

  • 1. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer.
    Sheng N; Yan L; Wu K; You W; Gong J; Hu L; Tan G; Chen H; Wang Z
    Cell Death Dis; 2018 Mar; 9(3):402. PubMed ID: 29540729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status.
    Agarwal S; Behring M; Kim HG; Chandrashekar DS; Chakravarthi BVSK; Gupta N; Bajpai P; Elkholy A; Al Diffalha S; Datta PK; Heslin MJ; Varambally S; Manne U
    Mol Oncol; 2020 Dec; 14(12):3007-3029. PubMed ID: 33037736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancer.
    Agarwal S; Afaq F; Bajpai P; Kim HG; Elkholy A; Behring M; Chandrashekar DS; Diffalha SA; Khushman M; Sugandha SP; Varambally S; Manne U
    Mol Oncol; 2022 Apr; 16(8):1728-1745. PubMed ID: 35194944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathway.
    Wang Y; Dong S; Hu K; Xu L; Feng Q; Li B; Wang G; Chen G; Zhang B; Jia X; Xu Z; Gao X; Zhang H; Xie Y; Lu M; Chang S; Song D; Wu X; Jia Q; Zhu H; Zhou J; Zhu W; Shi J
    J Transl Med; 2023 Nov; 21(1):858. PubMed ID: 38012658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting TRIP13 for overcoming anticancer drug resistance (Review).
    Zhao L; Ye S; Jing S; Gao YJ; He T
    Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRIP13 Activates Glycolysis to Promote Cell Stemness and Strengthen Doxorubicin Resistance of Colorectal Cancer Cells.
    Liu G; Wang H; Rui R; Wang Y; Li Y
    Curr Med Chem; 2024 Feb; ():. PubMed ID: 38347785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP24A1, AHR, CPEB4, TRIP13, and PIK3CA genes expression in colorectal cancer patients: novel diagnostic biomarkers.
    El Nakib AM; Elsaeed M; Abdelsalam RA; Wafi K; Elekhnawy E; Alrouji M; Alsaleem M; Aljarba NH; Batiha GE; Negm WA; Mostafa SA
    Eur Rev Med Pharmacol Sci; 2023 Sep; 27(17):7946-7955. PubMed ID: 37750623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TI17, a novel compound, exerts anti-MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage.
    Chang S; Xiao W; Xie Y; Xu Z; Li B; Wang G; Hu K; Zhang Y; Zhou J; Song D; Zhu H; Wu X; Lu Y; Shi J; Zhu W
    Cancer Med; 2023 Dec; 12(23):21321-21334. PubMed ID: 37942576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 14-3-3 Proteins: diverse functions in cell proliferation and cancer progression.
    Freeman AK; Morrison DK
    Semin Cell Dev Biol; 2011 Sep; 22(7):681-7. PubMed ID: 21884813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo.
    Dong S; Hu K; Shi Y; Wang G; Yu D; Zhao Y; Zhang H; Wang Y; Sun H; Xu Z; Jia Q; Li Y; Li Y; Li B; Shi J; Zhu W
    Bioorg Med Chem Lett; 2024 Jan; 98():129590. PubMed ID: 38092072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer.
    Dhasmana S; Dhasmana A; Rios S; Enriquez-Perez IA; Khan S; Afaq F; Haque S; Manne U; Yallapu MM; Chauhan SC
    Comput Struct Biotechnol J; 2023; 21():5765-5775. PubMed ID: 38074464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma.
    Li W; Zhang G; Li X; Wang X; Li Q; Hong L; Shen Y; Zhao C; Gong X; Chen Y; Zhou J
    Biochem Biophys Res Commun; 2018 May; 499(3):416-424. PubMed ID: 29567476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.
    Dong L; Ding H; Li Y; Xue D; Li Z; Liu Y; Zhang T; Zhou J; Wang P
    Int J Biol Macromol; 2019 Jan; 121():200-206. PubMed ID: 30267820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
    Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
    J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.
    Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z
    Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression.
    Yu L; Xiao Y; Zhou X; Wang J; Chen S; Peng T; Zhu X
    Biomed Pharmacother; 2019 Dec; 120():109508. PubMed ID: 31648166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.
    Gao Y; Liu S; Guo Q; Zhang S; Zhao Y; Wang H; Li T; Gong Y; Wang Y; Zhang T; Dong Z; Bacich D; Chowdhury WH; Rodriguez R; Wang Z
    Int J Biol Sci; 2019; 15(7):1488-1499. PubMed ID: 31337978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated TRIP13 drives cell proliferation and drug resistance in bladder cancer.
    Lu S; Guo M; Fan Z; Chen Y; Shi X; Gu C; Yang Y
    Am J Transl Res; 2019; 11(7):4397-4410. PubMed ID: 31396344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis.
    Zhang G; Zhu Q; Fu G; Hou J; Hu X; Cao J; Peng W; Wang X; Chen F; Cui H
    Br J Cancer; 2019 Dec; 121(12):1069-1078. PubMed ID: 31740732
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.